A practical reference on storage stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-24 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
In the case of tyrocidine, ring closure has been shown to be highly favorable due to 4 H-bonds helping the decapeptide backbone to adopt a stable conformation (See figure 5). This intramolecular cyclization occurs in a head-to-tail fashion involving the N-terminus of the D-Phe1 and the C-terminus of the L-Leu10 (See figure 4).
A polypeptide is a single linear chain of many amino acids (any length), held together by amide bonds. A protein consists of one or more polypeptides (more than about 50 amino acids long). An oligopeptide consists of only a few amino acids (between two and twenty).
=== Brand names === Escitalopram is sold under many brand names worldwide such as Cipralex, Lexapro, Lexam, Mozarin, Aciprex, Depralin, Ecytara, Elicea, Gatosil, Nexpram, Nexito, Nescital, Szetalo, Stalopam, Pramatis, Betesda, Scippa and Rexipra.
Despite being raised as a communicant of the Catholic Church, on January 19, 2016, Duterte clarified that he had not attended Mass for quite some time already since he deemed it incompatible with his mayoral responsibilities: "If I listened to the Ten Commandments or to the priests," said Duterte, "I would not be able to do anything as a mayor." Duterte has described himself as Christian in 2016 and "spiritual" in 2018, expressing that he "can't accept" Catholicism or organized religion but also that he is neither an atheist nor an agnostic. He has referred to God as Allah and has been quoted as saying: "a part of me which is Islam". During his presidency, Duterte and the Catholic Church in the Philippines exchanged frequent criticisms. In response to the rising death toll in Duterte's war on drugs, the Catholic Bishops' Conference of the Philippines (CBCP) in February 2017 issued a strongly worded pastoral letter which was read in church services; the letter highlighted that "[killing] is considered as normal", and "to consent and keep silent in front of evil is to be an accomplice to it". Duterte later lambasted Catholic bishops, telling them "not use the pulpit", reviling them as "sons of bitches", remarking that some of them are gay, and urging street bums to rob and kill them. Notable among the bishops Duterte criticized was Caloocan Bishop Pablo Virgilio David, a vocal critic of the Duterte administration's war on drugs.
Sources: en.wikipedia.org
Some wallets are specifically designed to be compatible with a framework. The European Union is creating an eIDAS compatible European Self-Sovereign Identity Framework (ESSIF) which runs on the European Blockchain Services Infrastructure (EBSI). The EBSI wallet is designed to (securely) provide information, an eID and to sign 'transactions'.
Cases of stigmatism fall into two categories: self-inflicted wounds, which may be either cases of fraud or of unconscious self-infliction, and those that are caused by emotional states ... Self-induced (through autosuggestion) itching and subsequent scratching of which the individual is unaware is likely to occur in suggestible persons if the stimulus is a mental or actual picture of the Crucifixion used during meditation and if the main motive is to receive the stigmata. The motive behind that may be unconscious conflict and a desire to escape from an intolerable situation into invalidism where one's needs are taken care of. It then becomes a case of hysterical conversion reaction. Many cases of stigmatism can be explained as fraud or unconsciously self-inflicted wounds. In his Stigmata: A Medieval Phenomenon in a Modern Age, Ted Harrison suggests that there is no single mechanism whereby the marks of stigmata were produced. Harrison found no evidence from a study of contemporary cases that the marks were supernatural in origin. He concluded, however, that marks of natural origin need not be hoaxes. Some stigmatics marked themselves in attempt to suffer with Christ as a form of piety. Others marked themselves accidentally and their marks were noted as stigmata by witnesses. Often marks of human origin produced profound and genuine religious responses. Harrison also noted that after Saint Francis of Assisi, the stigmata was "seen as a predominantly female experience" with the female-to-male ratio of stigmatics being 7 to 1.
===== Chain of any number of decays ===== For the general case of any number of consecutive decays in a decay chain, i.e. A1 → A2 ··· → Ai ··· → AD, where D is the number of decays and i is a dummy index (i = 1, 2, 3, ..., D), each nuclide population can be found in terms of the previous population. In this case N2 = 0, N3 = 0, ..., ND = 0. Using the above result in a recursive form:
Eye exposure: 18 mg (0.28 gr)/6 hours (rabbit) Oral: 72 mg/kg (0.00115 oz/lb) (rat, LD50), 1,186 mg/kg (0.01898 oz/lb) (rat, TDLo), 5,112 mg/kg (0.08179 oz/lb) (rat, TD) Inhalation: 12,500 ppm (human, TCLo), 960 ppm/4 hours (dog, LC50) 33–50 ppm (rat or mouse, TC), 800 ppm/4 hours (rat or mouse, LC50) Subcutaneous injection: 100 mg/kg (0.0016 oz/lb) (cat, LDLo), 292 mg/kg (0.00467 oz/lb) (mouse, TDLo) 900–2,600 mg/kg (0.014–0.042 oz/lb) (mouse, TD), 187 mg/kg (0.00299 oz/lb) (rat, LD50). Intraperitoneal injection: 750 mg/kg (0.0120 oz/lb) (mouse, TDLo), 175 mg/kg (0.00280 oz/lb) (mouse, LD50) Intravenous injection: 175 mg/kg (0.00280 oz/lb) (rabbit, LD50), 290 mg/kg (0.0046 oz/lb) (mouse, LD50) The US Environmental Protection Agency (USEPA) estimated in 2016 that for low doses, the inhalation of ethylene oxide for a lifetime could increase an individual's lifetime cancer risk by as much as 3.0 × 10−3 per μg/m3 (without considering that early-life exposures are likely more potent). The USEPA estimated the slope of the dose-response declines at higher doses, and extra cancer risk estimates for several occupational exposure scenarios are calculated.
Peptidoglycan (PG) is a mesh-like structure containing polysaccharides cross-linked by peptide chains. Penicillin-binding proteins (DD-transpeptidases), in short PBPs, recognize the PG peptides and catalyze the cross-linking reactions. These enzymes are reported to have high specificity toward the chirality center of the amino acid backbone (D-chiral center) but relatively low specificity toward the side-chain structure. Therefore, when FDAAs are present, they are taken by PBPs for the cross-linking reactions, resulting in their incorporation into the PG peptide chains. At proper concentration, e.g. 1–2 mM, FDAAs labeling does not affect PG synthesis and cell growth because only 1%–2% of PG peptide chains are labeled with FDAA.
Sources: en.wikipedia.org
Designed for the Kill: The Jet Fighter—Development and Experience. United States Naval Institute, 1995, ISBN 0-87021-059-9. Stevenson, James. The Pentagon Paradox: The Development of the F-18 Hornet. Naval Institute Press, 1993, ISBN 1-55750-775-9. Tillman, Barrett. Hellcat Aces of World War 2. London: Osprey Aerospace, 1996. ISBN 1-85532-596-9. United States Air Force Museum Guidebook. Wright-Patterson AFB, Ohio: Air Force Museum Foundation, 1975. United States Army Air Force. AN 01-60JE-2: Maintenance and Erection Instructions for Army Model P-51D-5, −10, −15, 20, −25; P-51K-1, −5, −10, −15; British Model Mustang IV Aeroplanes. Evansville, Indiana: U.S.A.A.F, 1944. Wagner, Ray. American Combat Planes of the 20th Century. Reno, Nevada: Jack Bacon & Company, 2004. ISBN 978-0-930083-17-5. Wagner, Ray. Mustang Designer: Edgar Schmued and the P-51. Herndon, Virginia: Smithsonian Institution Press, 2000. ISBN 978-1-56098-994-3. Walker, Jeff. "Empire of the Sun." Air Classics, Volume 24, Number 1, January 1988. White, Graham. Allied Aircraft Piston Engines of World War II. Warrendale, Pennsylvania: Society for Automotive Engineers, 1995. ISBN 1-56091-655-9. Wilson, Stewart, ed. "Mustang Warbirds: Civil Registered Mustangs of Australia and New Zealand Then and Now." Warbirds of Australia and New Zealand 2010. St Leonards, New South Wales, Australia: Chevron Publishing Group, 2010. Wixey, Ken. "Magnificent Mustang: A Production History of the North American P-51." Air Enthusiast, Issue 95, September/October 2001. Yenne, Bill: Rockwell: The Heritage of North American.
The two substrates of this enzyme are (S)-carnitine and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 3-dehydrocarnitine, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-carnitine:NAD+ oxidoreductase.
) and a high filling factor, resulting in a strong coupling between the probe coil and the sample. The phenomenon is also impacted by the concentration of the nuclei within the sample and their magnetic moments, which can intensify the effects of radiation damping. The strength of the magnetic field is inversely proportional to the lifetime of RD. The impact of radiation damping on NMR signals is multifaceted. It can accelerate the decay of the NMR signal faster than intrinsic relaxation processes would suggest. This acceleration can complicate the interpretation of NMR spectra by causing broadening of spectral lines, distorting multiplet structures, and introducing artifacts, especially in high-resolution NMR scenarios. Such effects make it challenging to obtain clear and accurate data without considering the influence of radiation damping. To mitigate these effects, various strategies are employed in NMR spectroscopy. These methods majorly stem from hardware or software. Hardware modifications including RF feed-circuit and Q-factor switches reduce the feedback loop between the sample magnetization and the electromagnetic field induced by the coil and function successfully. Other approaches such as designing selective pulse sequences also effectively manage the fields induced by radiation damping. These approaches aim to control and limit the disruptive effects of radiation damping during NMR experiments and all approaches are successful in eliminating RD to a fairly large extent.
=== 2007–2013 === Helton's power and RBI production stayed relatively level to his previous year's stats during the 2007 season, as he managed 17 home runs and 91 RBI. These numbers were well below his career norms, yet Helton kept up his string of seven consecutive seasons with an on-base percentage higher than .400, nine consecutive seasons with a batting average above .300, and also walked more times than he struck out (a feat he accomplished in seven of his first ten full seasons). Helton recorded his 1,000th career hit at Coors Field on June 20, in a 6–1 home win over the New York Yankees, becoming only the fifth active player to have 1,000 career hits in one ballpark. On September 9, in 4–2 home victory over the San Diego Padres, Helton hit his 35th double of the season. This made him the only player in MLB history to have hit 35 or more doubles in at least 10 consecutive seasons (1998–2007). Helton hit his 300th career home run on September 16 in a 13–0 home win over the Florida Marlins. He became the first player to hit 300 home runs for the Rockies. The 2007 season was a wild see-saw affair for the Rockies. After they began the season with a 13-1 record, threatening to run away with the division, they underwent multiple red hot and ice cold streaks, leaving them in a desperate spot in September, as they tried to earn a playoff spot for the first time since their brief October appearance of 1995.
The Treaty on European Union (TEU) and the Treaty on the Functioning of the European Union (TFEU) are the two main sources of EU law. Representing agreements between all member states, the TEU focuses more on principles of democracy, human rights, and summarises the institutions, while the TFEU expands on all principles and fields of policy in which the EU can legislate. In principle, the EU treaties are like any other international agreement, which will usually be interpreted according to principles codified by the Vienna Convention 1969. It can be amended by unanimous agreement at any time, but TEU itself, in article 48, sets out an amendment procedure through proposals via the Council and a Convention of national Parliament representatives. Under TEU article 5(2), the "principle of conferral" says the EU can do nothing except the things which it has express authority to do. The limits of its competence are governed by the Court of Justice, and the courts and Parliaments of member states. Under TEU article 6(1), the Charter of Fundamental Rights of the European Union (CFR) has the same legal value as the Treaties (TEU & TFEU). It does not, however, extend the competences of the EU. It serves as a set of fundamental rights which all EU legislation has to respect, whether it is an EU institution or a member state which executes those laws. As the European Union has grown from 6 to 27 member states, a clear procedure for accession of members is set out in TEU article 49.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.